tiprankstipranks
Vor Biopharma (VOR)
NASDAQ:VOR
US Market

Vor Biopharma (VOR) Income Statement

500 Followers

Vor Biopharma Income Statement

Last quarter (Q4 2023), Vor Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Vor Biopharma's net income was $-26.26M. See Vor Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 126.04M$ 126.04M$ 93.42M$ 69.02M$ 43.37M$ 10.42M
Operating Income
$ -126.04M$ -126.04M$ -93.42M$ -69.02M$ -43.37M$ -10.42M
Net Non Operating Interest Income Expense
$ 8.17M$ 8.17M$ 1.32M$ 119.00K$ 29.00K$ -454.00K
Other Income Expense
-----$ 32.00K
Pretax Income
$ -117.86M$ -117.86M$ -92.09M$ -68.90M$ -43.34M$ -10.84M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -117.86M$ -117.86M$ -92.09M$ -70.13M$ -49.26M$ -12.61M
Basic EPS
$ -1.76$ -1.75$ -2.33$ -2.10$ -1.42$ -1.91
Diluted EPS
$ -1.76$ -1.75$ -2.33$ -2.10$ -1.42$ -1.91
Basic Average Shares
$ 268.77M$ 67.19M$ 39.55M$ 33.43M$ 34.64M$ 5.66M
Diluted Average Shares
$ 268.77M$ 67.19M$ 39.55M$ 33.43M$ 34.64M$ 5.66M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 126.04M$ 126.04M$ 93.42M$ 69.02M$ 43.37M$ 10.42M
Net Income From Continuing And Discontinued Operation
$ -117.86M$ -117.86M$ -92.09M$ -68.90M$ -43.34M$ -10.84M
Normalized Income
$ -49.90M-$ -72.75M-$ -43.34M$ -10.87M
Interest Expense
----$ 0.00$ 608.00K
EBIT
$ -123.84M$ -126.04M$ -92.09M$ -69.02M$ -43.37M$ -10.23M
EBITDA
$ -121.38M$ -122.54M$ -89.59M$ -67.62M$ -42.76M$ -10.14M
Currency in USD

Vor Biopharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis